A Study to Improve the Collaboration Between Primary and Secondary Health Care on the Treatment of Osteoporosis After a Hip Fracture.

Launched by UNIVERSITY HOSPITAL, AKERSHUS · Jun 6, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on improving the way primary care doctors and hospitals work together to treat osteoporosis in patients who have suffered a hip fracture. Specifically, it aims to help older adults, aged 75 and up, receive a special treatment called zoledronic acid, which is given through an infusion, along with vitamin D and calcium to help prevent further fractures. After being treated at the hospital, patients will be followed up by their general practitioners to make sure they continue receiving this treatment for three years. The study will have two groups: one group will receive additional support from nurses at the hospital to help manage their treatment, while the other group will receive the usual care without this extra support.

To participate in this trial, you need to be 75 years or older and have experienced a hip fracture. However, if you refuse treatment, have other osteoporosis treatments recommended, or have dementia, you won’t be eligible. If you join the study, you can expect to receive the initial treatment at the hospital and then follow-up care from your doctor, with a chance to provide feedback about your treatment after one year. The goal is to see if the group receiving the extra support has better follow-up care compared to the usual treatment group.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients 75 years or older with a hip fracture
• Exclusion Criteria:
• • Refuse treatment
• • Another treatment of osteoporosis is indicated
• • Guest patient, do not live in the admission area
• • Dementia